1608140-48-2

Usage

Uses

Used in Pharmaceutical Industry:
C₃₄H₅₄N₂O₁₄ is used as a novel pain management medication for its improved safety and efficacy profiles. It is particularly useful in managing chronic and severe pain conditions, as it exhibits a lower potential for tolerance and dependence compared to traditional opioids.
Used as an Analgesic Agent:
Nucleomorphin is used as an analgesic agent due to its ability to provide pain relief with reduced side effects. Its mixed agonist-antagonist activity at opioid receptors contributes to its lower potential for tolerance and dependence, making it a promising alternative to conventional opioids.
Used in Research and Development:
C₃₄H₅₄N₂O₁₄ is used in research and development for further exploration of its potential as a pain relief medication. Its unique structure and pharmacological properties make it an interesting subject for studies aimed at understanding its mechanism of action and optimizing its therapeutic benefits.

Upstream product

• 756526-04-2 1-amino-3,6,9.12,15,18,21,24-octaoxaheptacosan-27-oic acid 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 1352642-02-4 ((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)methyl (2,5-dioxopyrrolidin-1-yl) carbonate 

Relevant academic research and scientific papers

SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION

The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Qlcapable of reacting with a functional group F1present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1of a linker-conjugate according to the invention with a functional group F1of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention. In a preferred embodiment, the invention concerns a process for the preparation of a bioconjugate via a cycloaddition, such as a (4+2)-cycloaddition (e.g. a Diels-Alder reaction) or a (3+2)-cycloaddition (e.g. a 1,3-dipolar cycloaddition).

MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to an antibody comprising a GlcNAc-S(A)x substituent, wherein S(A)x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)x substituent is bonded to the antibody via CI of the N-acetylglucosamine of said GlcNAc-S(A)x substituent, and wherein said N-acetylglucosamine is optionally fucosylated. The invention also relates to an antibody-conjugate, in particular to an antibody- conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N- acetylglucosamine is optionally fucosylated (b is 0 or 1). The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament. In addition, the invention relates to a kit of parts comprising an azide-modified antibody and a linker-conjugate, wherein said linker-conjugate comprises a (hetero)cycloalkynyl group and one or more molecules of interest.